Evidence map›Paper›PMID 35137250›Full record

ArticleArchives of virology2022

Diagnostic performance and clinical feasibility of a novel one-step RT-qPCR assay for simultaneous detection of multiple severe acute respiratory syndrome coronaviruses.

Tran Bac Le, Hye Kwon Kim, Min-Ju Ahn, Mark Zanin, Van Thi Lo, Shiman Ling, Zhanpeng Jiang, Jung-Ah Kang, Pan Kee Bae, Yeon-Sook Kim and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Archives of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Tran Bac Le *Bio-nanotechnology Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, South Korea.
Hye Kwon Kim *Chungbuk National University, Cheongju, South Korea.
Min-Ju Ahn *Bio-nanotechnology Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, South Korea.
Mark Zanin *State Key Laboratory for Respiratory Diseases, Guangzhou Medical University, Guangzhou, Guangdong Province, China.
Van Thi LoBio-nanotechnology Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, South Korea.
Shiman LingState Key Laboratory for Respiratory Diseases, Guangzhou Medical University, Guangzhou, Guangdong Province, China.
Zhanpeng JiangState Key Laboratory for Respiratory Diseases, Guangzhou Medical University, Guangzhou, Guangdong Province, China.
Jung-Ah KangBio-nanotechnology Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, South Korea.
Pan Kee BaeBioNano Health Guard Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, South Korea.
Yeon-Sook KimChungnam National University School of Medicine, Daejeon, South Korea.
Seungtaek KimInstitute Pasteur Korea, Seongnam-si, South Korea.
Sook-San WongState Key Laboratory for Respiratory Diseases, Guangzhou Medical University, Guangzhou, Guangdong Province, China. sook-san.wong@gird.cn.
Dae Gwin JeongBio-nanotechnology Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, South Korea. dgjeong@kribb.re.kr.
Sun-Woo YoonBio-nanotechnology Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, South Korea. syoon@kribb.re.kr.ORCID http://orcid.org/0000-0003-2061-9743
Korea Research Institute of Bioscience and Biotechnology · KRState Key Laboratory of Respiratory Disease · CNChungbuk National University · KRChungnam National University · KRInstitut Pasteur Korea · KR

Funding

Ministry of Science, ICT and Future Planning H-GUARD 2013M3A6B2078954National Research Foundation of Korea 2020R1A2C2009262
6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) is an acute respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Other coronaviruses (CoVs) can also infect humans, although the majority cause only mild respiratory symptoms. Because early diagnosis of SARS-CoV-2 is critical for preventing further transmission events and improving clinical outcomes, it is important to be able to distinguish SARS-CoV-2 from other SARS-related CoVs in respiratory samples. Therefore, we developed and evaluated a novel reverse transcription quantitative polymerase chain reaction (RT-qPCR) assay targeting the genes encoding the spike (S) and membrane (M) proteins to enable the rapid identification of SARS-CoV-2, including several new circulating variants and other emerging SARS-like CoVs. By analysis of in vitro-transcribed mRNA, we established multiplex RT-qPCR assays capable of detecting 5 × 10° copies/reaction. Using RNA extracted from cell culture supernatants, our multiple simultaneous SARS-CoV-2 assays had a limit of detection of 1 × 10° TCID

Indexed as

COVID-19Clinical Laboratory TechniquesFeasibility StudiesHumansReal-Time Polymerase Chain ReactionSARS-CoV-2Sensitivity and Specificity

Identifiers

PMID35137250
PMCPMC8885489
OpenAlexW4210940106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.